Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $37.56
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price […]
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price […]
